Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Der er noget nær reklamekrig mellem medicinalfirmaer i USA, og danske Novo Nordisk er endt midt i kampens hede.

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

»Man siger jo også, at spredning er redning, og det er vigtigt at sprede sin risiko. Man kan godt kun snakke om, hvor stort ...

Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Eli Lilly er danske Novo Nordisks største konkurrent på medicinalmarkedet inden for diabetes og overvægt. Novo ...

Recently, the Centers for Medicare & Medicaid Services (CMS) included Novo Nordisk’s key GLP-1 drugs, Ozempic and Wegovy, in its list of 15 drugs for Medicare price negotiations. This announcement ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...